CD70 and nonpapillary renal cell carcinoma: In probing the immune landscape of RMC, we demonstrated that heterogenous expression of CD70 by a distinct sub-population of malignant cells appears to be a general feature of both RMC and ccRCC (43, 66), and could therefore be considered as a viable target for RCC therapy (65).